Elevance Health, Inc. (FRA:A58)
Germany · Delayed Price · Currency is EUR | Market Cap | 75.25B -1.0% |
| Revenue (ttm) | 173.82B +9.4% |
| Net Income | 4.55B -11.4% |
| EPS | 20.40 -8.1% |
| Shares Out | n/a |
| PE Ratio | 16.55 |
| Forward PE | 15.25 |
| Dividend | 5.90 (1.75%) |
| Ex-Dividend Date | Jun 10, 2026 |
| Volume | n/a |
| Open | 338.80 |
| Previous Close | 337.70 |
| Day's Range | 338.80 - 338.80 |
| 52-Week Range | 235.80 - 366.00 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Jul 15, 2026 |
About Elevance Health
Elevance Health, Inc., together with its subsidiaries, operates as a health benefits company in the United States. The company operates in four segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other. It offers a variety of health plans and services to individual, employer group risk-based and fee-based, BlueCard, Medicare, Medicaid, and FEP members; health products; a broad array of fee-based administrative managed care services; and specialty and other insurance products and services, such as stop loss, dental, vision, a... [Read more]
Financial Performance
In 2025, Elevance Health's revenue was $199.13 billion, an increase of 12.62% compared to the previous year's $176.81 billion. Earnings were $5.66 billion, a decrease of -5.32%.
Financial numbers in USD Financial StatementsNews
New Elevance Health Public Policy Institute Study Examines Payment Disputes for Planned Procedures Under the No Surprises Act
INDIANAPOLIS--(BUSINESS WIRE)--The No Surprises Act was created to protect patients from unexpected medical bills. While those patient protections are working, new research from the Elevance Health Pu...
Thomas Carr Howe Middle School Unveils New Fitness and Strength Training Space Through Partnership with Elevance Health and Impact Fitness Foundation
INDIANAPOLIS--(BUSINESS WIRE)--Thomas Carr Howe Middle School today celebrated the unveiling of a newly transformed fitness and strength training space made possible through a partnership with Elevanc...
Elevance Health announces advancements for clinical review with Health OS
Elevance Health (ELV) announced advancements in how it helps streamline clinical review and create a simpler, faster, and more connected experience for care providers and members through Health OS. Th...
Elevance Health Makes Clinical Review Faster, More Connected with Health OS
INDIANAPOLIS--(BUSINESS WIRE)--Elevance Health today announced advancements in how it helps streamline clinical review and create a simpler, faster, and more connected experience for care providers an...
Elevance Health Announces $640 Million Investment in Affordable Housing Over the Past Five Years, Surpassing $1 Billion in Total Commitment Nationwide
INDIANAPOLIS--(BUSINESS WIRE)--Elevance Health (NYSE: ELV) today announced it has invested $640 million in affordable housing over the past five years, building on more than $1 billion invested over n...
Elevance Health Makes Chronic Care Easier to Navigate With Connected, Personalized Support
INDIANAPOLIS--(BUSINESS WIRE)--Across the country, three in four adults are living with at least one chronic condition. Elevance Health is helping people manage chronic conditions by creating more per...
Elevance Health Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026
Progress with CMS on Medicare Advantage sanctions is nearly complete, with no expected impact on enrollment or margins. Utilization trends support earnings guidance, while Medicaid margins are set to improve after a 2026 trough. Growth is driven by disciplined pricing, Carelon integration, and technology investments.
Elevance Health price target raised to $476 from $411 at JPMorgan
JPMorgan raised the firm’s price target on Elevance Health (ELV) to $476 from $411 and keeps an Overweight rating on the shares. The firm updated healthcare service models. Published first…
Elevance Health price target raised to $465 from $435 at Mizuho
Mizuho raised the firm’s price target on Elevance Health (ELV) to $465 from $435 and keeps an Outperform rating on the shares. The firm believes the managed care sector is…
Elevance Health price target raised to $404 from $352 at Morgan Stanley
Morgan Stanley raised the firm’s price target on Elevance Health (ELV) to $404 from $352 and keeps an Equal Weight rating on the shares. Managed care stocks have been “grinding…
Elevance Health price target raised to $460 from $435 at BofA
BofA analyst Kevin Fischbeck raised the firm’s price target on Elevance Health (ELV) to $460 from $435 and keeps a Buy rating on the shares. Data points continue to trickle…
Elevance Health participates in a conference call with JPMorgan
Healthcare Services Analyst holds a conference call with management on June 2 at 1 pm hosted by JPMorgan.Webcast Link
Elevance Health price target raised to $450 from $375 at Truist
Truist analyst David MacDonald raised the firm’s price target on Elevance Health (ELV) to $450 from $375 and keeps a Buy rating on the shares as part of a broader…
CMS says Elevance avoids sanctions after corrective action plan progress
The Centers for Medicare & Medicaid Services notified Elevance Health (ELV) that the company has completed Step 2 of its corrective action plan related to potential Medicare Advantage enrollment sanct...
Elevance makes progress toward resolving MA sanctions, Wells Fargo says
Wells Fargo analyst Stephen Baxter says that based on a new Centers for Medicare & Medicaid Services document just posted, Elevance Health (ELV) appears to be making progress to resolve…
Elevance Health Expands Access to Digital Tools, Helping Bridge the Healthcare Digital Divide
INDIANAPOLIS--(BUSINESS WIRE)--Elevance Health is advancing its commitment to improving healthcare access by addressing one of healthcare's most pressing challenges: the digital divide. Through innova...
Elevance Health price target raised to $480 from $408 at Barclays
Barclays analyst Andrew Mok raised the firm’s price target on Elevance Health (ELV) to $480 from $408 and keeps an Overweight rating on the shares. The firm believes the managed…
Elevance Health price target raised to $460 from $400 at UBS
UBS raised the firm’s price target on Elevance Health (ELV) to $460 from $400 and keeps a Buy rating on the shares. Managed care organizations broadly raised guidance after stronger-than-expected…
Elevance Health upgraded to Buy from Hold at Deutsche Bank
Deutsche Bank upgraded Elevance Health (ELV) to Buy from Hold with a price target of $498, up from $363. The firm upgraded three managed care names citing a stabilizing managed…
Elevance Health price target raised to $435 from $385 at Mizuho
Mizuho raised the firm’s price target on Elevance Health (ELV) to $435 from $385 and keeps an Outperform rating on the shares. The firm views the Q1 reports in the…
Elevance Health upgraded to Buy from Hold at Deutsche Bank
Deutsche Bank upgraded Elevance Health (ELV) to Buy from Hold with a price target of $498, up from $363.
Elevance Health added to ‘Tactical Outperform’ list at Evercore ISI
Evercore ISI is adding Elevance Health (ELV) to the firm’s “Tactical Outperform” list for Q2, telling investors that the company is poised for “significant upside EPS this year” if current…
Easing medical costs a positive for health insurers, but real test lies ahead, analysts say
U.S. health insurers' strong first-quarter results signaled more stable medical costs after prolonged pressure, but Wall Street analysts want to see another similar quarter before they are convinced.
Elevance Health Transcript: AGM 2026
The meeting covered strong financial growth, board updates, and strategic initiatives in efficiency, digital transformation, and value-based care. All board proposals passed, while a shareholder proposal on political contributions failed.